ES2105679T3 - Benzoato de (s)-alfa-fenil-2-piridinetanamina y su uso como medicamento. - Google Patents

Benzoato de (s)-alfa-fenil-2-piridinetanamina y su uso como medicamento.

Info

Publication number
ES2105679T3
ES2105679T3 ES94912016T ES94912016T ES2105679T3 ES 2105679 T3 ES2105679 T3 ES 2105679T3 ES 94912016 T ES94912016 T ES 94912016T ES 94912016 T ES94912016 T ES 94912016T ES 2105679 T3 ES2105679 T3 ES 2105679T3
Authority
ES
Spain
Prior art keywords
phenyl
alpha
medicinal product
pyridineethanamine
benzoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912016T
Other languages
English (en)
Inventor
Robert John Murray
Donald Mathisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1993/000689 external-priority patent/WO1993020052A1/en
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2105679T3 publication Critical patent/ES2105679T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

EL BENZOATO DE (S)- AL -FENIL-2-PIRIDINETANAMINA ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS. ES UN AGENTE CONTRA LAS CONVULSIONES Y NEUROPROTECTOR.
ES94912016T 1993-04-01 1994-04-05 Benzoato de (s)-alfa-fenil-2-piridinetanamina y su uso como medicamento. Expired - Lifetime ES2105679T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
ES2105679T3 true ES2105679T3 (es) 1997-10-16

Family

ID=10728731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912016T Expired - Lifetime ES2105679T3 (es) 1993-04-01 1994-04-05 Benzoato de (s)-alfa-fenil-2-piridinetanamina y su uso como medicamento.

Country Status (13)

Country Link
EP (1) EP0691958B1 (es)
JP (1) JP3023988B2 (es)
AT (1) ATE156814T1 (es)
AU (1) AU682350B2 (es)
CA (1) CA2159480C (es)
DE (1) DE69404975T2 (es)
DK (1) DK0691958T3 (es)
ES (1) ES2105679T3 (es)
FI (1) FI109019B (es)
GR (1) GR3025082T3 (es)
NO (1) NO304648B1 (es)
WO (1) WO1994022832A1 (es)
ZA (1) ZA942140B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
JP2514855B2 (ja) * 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
DE69317411T2 (de) * 1992-04-03 1998-07-30 Ab Astra, Soedertaelje Enantiomere 1-phenyl-2-(2-pyridinyl)ethylamin für die behandlung neurodegenerativer störungen

Also Published As

Publication number Publication date
EP0691958B1 (en) 1997-08-13
CA2159480A1 (en) 1994-10-13
GR3025082T3 (en) 1998-01-30
FI109019B (fi) 2002-05-15
AU682350B2 (en) 1997-10-02
ATE156814T1 (de) 1997-08-15
WO1994022832A1 (en) 1994-10-13
CA2159480C (en) 2005-01-25
EP0691958A1 (en) 1996-01-17
NO953847L (no) 1995-11-22
JP3023988B2 (ja) 2000-03-21
DK0691958T3 (da) 1997-12-08
FI954646A0 (fi) 1995-09-29
DE69404975D1 (de) 1997-09-18
FI954646L (fi) 1995-11-29
ZA942140B (en) 1994-10-03
NO304648B1 (no) 1999-01-25
DE69404975T2 (de) 1997-12-18
JPH08508475A (ja) 1996-09-10
NO953847D0 (no) 1995-09-28
AU6433794A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
ES2137372T3 (es) Solucion antifungica para las uñas.
CA2132369A1 (en) Use for the Treatment of Mixed Skins, of an Effective Quantity of Active Substances
PT929565E (pt) Esteres de nitrato de compostos corticoides e suas aplicacoes farmaceuticas
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
ES2105672T3 (es) (s)-malato de (s)-alfa-fenil-2-piridinetanamina y su utilizacion como medicamento.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ES2115055T3 (es) 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
BG101126A (en) The use of muramylpeptide compounds
ES2105679T3 (es) Benzoato de (s)-alfa-fenil-2-piridinetanamina y su uso como medicamento.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
MX9307679A (es) Derivados de furanona utiles en terapia.
SE9501247D0 (sv) Anordning vid en så kallad strålkniv
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
MX9305151A (es) Metodo para el tratamiento de enfermedades de la piel.
ES2174081T3 (es) Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos.
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 691958

Country of ref document: ES